## Remarks

. . .

The July 12, 2007 Advisory Action indicated that the proposed amendments of July 2, 2007 would require further search and/or consideration. This RCE is intended to provide that opportunity, without the restrictions of after final practice.

The Advisory Action also expressed a concern that the marker protein should be described with more specific reference to the SEQ. ID. No. 1 (or the phosphorylated version thereof) to avoid a possible new matter issue. That has now been done.

The July 12, 2007 Advisory Action indicated some concerns regarding how the strike outs and underlinings were proposed in the July 2, 2007 amendment (apparently with respect to claim 1). To avoid any concerns in that regard, the subject matter of interest in previously submitted proposed claim 1 is now presented as a new claim 17. This should resolve any questions of this type.

Hence, this application is now believed to be in condition for allowance. No additional fee is believed necessary for the consideration of this amendment except for the RCE fee. However, if one is, please charge Deposit Account 17-0055 for the needed fees.

Respectfull submitted

Majed M Hamaw

Dated: July 2, 2007

By:
Carl K. Schwartz
Quarles & Brady LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202
(414) 277-5715
Reg. No. 29.437

MKE\6148203.1